Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJ7K9G
|
|||
| Drug Name |
RBN-2397
|
|||
| Synonyms |
2381037-82-5; Atamparib; Atamparib [INN]; UNII-B1MW2ME77A; B1MW2ME77A; SCHEMBL21521281; RBN2397; BCP33764; EX-A4038; RBN2397;RBN 2397; NSC825956; s8993; NSC-825956; HY-136174; CS-0120272; 3(2H)-Pyridazinone, 5-(((1S)-1-methyl-2-(3-oxo-3-(4-(5-(trifluoromethyl)-2-pyrimidinyl)-1-piperazinyl)propoxy)ethyl)amino)-4-(trifluoromethyl)-; 5-(((2S)-1-(3-Oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2- yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4- (trifluoromethyl)pyridazin-3(2H)-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Ribon Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H23F6N7O3
|
|||
| Canonical SMILES |
CC(COCCC(=O)N1CCN(CC1)C2=NC=C(C=N2)C(F)(F)F)NC3=C(C(=O)NN=C3)C(F)(F)F
|
|||
| InChI |
1S/C20H23F6N7O3/c1-12(30-14-10-29-31-17(35)16(14)20(24,25)26)11-36-7-2-15(34)32-3-5-33(6-4-32)18-27-8-13(9-28-18)19(21,22)23/h8-10,12H,2-7,11H2,1H3,(H2,30,31,35)/t12-/m0/s1
|
|||
| InChIKey |
UQZCQKXJAXKZQH-LBPRGKRZSA-N
|
|||
| CAS Number |
CAS 2381037-82-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Protein mono-ADP-ribosyltransferase TIPARP (TIPARP) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04053673) RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors , FIH, MAD Study. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Ribon Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.